This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bart-Delabesse, E. Articles by Datry, A. Search for Related Content PubMed PubMed Citation Articles by Bart-Delabesse, E. Articles by Datry, A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, October 2005, p. 5214-5220, Vol. 43, No. 10
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.10.5214-5220.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Detection of Aspergillus Galactomannan Antigenemia To Determine Biological and Clinical Implications of Beta-Lactam Treatments

Emmanuelle Bart-Delabesse,^1* Maria Basile,² Ahmad Al Jijakli,^2, Didier Souville,¹ Frédérick Gay,¹ Bruno Philippe,³ Philippe Bossi,⁴ Martin Danis,¹ Jean-Paul Vernant,² and Annick Datry¹

Laboratoire de Parasitologie et Mycologie,¹ Service d'Hématologie Clinique,² Service de Maladies Infectieuses, Groupe Hospitalo-Universitaire Pitié-Salpêtrière, Paris, France,⁴ Service de Pneumologie, Hôpital Foch, Suresnes, France³

Received 29 March 2005/ Returned for modification 20 April 2005/ Accepted 28 June 2005

Detection of Aspergillus galactomannan (GM) in serum with the Platelia Aspergillus enzyme immunoassay (EIA) is useful for diagnosing invasive aspergillosis. From May 2003 to November 2004, 65 patients who did not develop aspergillosis had at least two positive sera while receiving a beta-lactam treatment (GM index [GMI], 0.5). Of the 69 treatment episodes scored, 41 consisted of a beta-lactam other than piperacillin-tazobactam (n = 29), namely, amoxicillin-clavulanate (n = 25), amoxicillin (n = 10), ampicillin (n = 3), or phenoxymethylpenicillin (n = 2). In all cases, antigenemia became negative 24 h to 120 h upon stopping the antibiotic. Monitoring of 35 patients, including 26 with hematological malignancies, revealed three antigenemia kinetic patterns: each was observed with any drug regimen and consisted of a persistent GMI of >2.0 (65.7%), >0.5, and 1.5 (25.7%) or a variable GMI (14.3%) from the onset of antibiotic therapy. All available drug batches given to 26 patients cross-reacted with the EIA. Galactomannan titration in batches failed to predict the GM titers in the five patients studied at cumulative doses of ampicillin or amoxicillin-clavulanate, regardless of the time lapse between serum sampling and infusion period. Our results show that beta-lactams other than piperacillin-tazobactam may lead to false presumption of aspergillosis. The resulting kinetic patterns of GM antigenemia are variable, and sampling serum prior to the next beta-lactam dose may not decrease GMI below the threshold. Consequently, testing of suspected antibiotic batches remains the only indicator of possible false EIA positivity.

Present address: Service d'Hématologie Clinique, Centre Hospitalier Victor Dupouy, Argenteuil, France.

This article has been cited by other articles:

• Orlopp, K., von Lilienfeld-Toal, M., Marklein, G., Reiffert, S. M., Welter, A., Hahn-Ast, C., Purr, I., Gorschluter, M., Molitor, E., Glasmacher, A. (2008). False positivity of the Aspergillus galactomannan Platelia ELISA because of piperacillin/tazobactam treatment: does it represent a clinical problem?. J Antimicrob Chemother 0: dkn308v1-4 [Abstract] [Full Text]  
• Machetti, M., Majabo, M. J., Furfaro, E., Solari, N., Novelli, A., Cafiero, F., Viscoli, C. (2006). Kinetics of galactomannan in surgical patients receiving perioperative piperacillin/tazobactam prophylaxis. J Antimicrob Chemother 58: 806-810 [Abstract] [Full Text]